InVivo Therapeutics (NSDQ:NVIV) said today that the 8th patient enrolled in a clinical trial of its spinal scaffold succumbed to his injuries nearly 5 days after a severe car accident. The death appears to be unrelated to InVivo’s bioresorbable neuro-spinal scaffold, which is designed to help heal traumatic spinal cord injuries.
The patient was implanted April 12 with the InVivo device about 71 hours after the car crash, by principal investigator Dr. Travis Dumont of Tucson’s Banner University Medical Center,the Cambridge, Mass.-based company said. The patient died from his injuries 2 days later, InVivo said.
“Our thoughts are with the patient’s loved ones during this very difficult time. The staff and Dr. Dumont at Banner attempted to give this patient the hope of an improved neurological outcome, but unfortunately he was not able to overcome the severe nature of his injuries,” chairman & CEO Mark Perrin said in prepared remarks.
Dumont determined that the cause of death was unrelated to the InVivo device or its implantation procedure, but the case will still be reviewed by , The cause of death was determined by the Principal Investigator to be unrelated to the Neuro-Spinal Scaffold device or implantation procedure and will be reviewed by the Data & Safety Monitoring Board and the FDA, the company said.
InVivo said it’s still enrolling patients in the Inspire trial.
NVIV shares were down -6.4% to $6.10 apiece today in mid-day trading.
